Eterna Therapeutics Inc. (NASDAQ:ERNA) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in Eterna Therapeutics Inc. (NASDAQ:ERNA) by 30.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,898 shares of the company’s stock after acquiring an additional 5,830 shares during the quarter. Vanguard Group Inc.’s holdings in Eterna Therapeutics were worth $54,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new stake in shares of Eterna Therapeutics in the fourth quarter valued at $45,000. Renaissance Technologies LLC purchased a new stake in shares of Eterna Therapeutics in the fourth quarter valued at $56,000. CI Private Wealth LLC purchased a new stake in shares of Eterna Therapeutics in the fourth quarter valued at $197,000. Goldman Sachs Group Inc. purchased a new stake in shares of Eterna Therapeutics in the second quarter valued at $26,000. Finally, Sippican Capital Advisors grew its position in shares of Eterna Therapeutics by 60.0% in the second quarter. Sippican Capital Advisors now owns 21,601 shares of the company’s stock valued at $49,000 after purchasing an additional 8,101 shares during the period. 70.55% of the stock is owned by institutional investors and hedge funds.

Eterna Therapeutics Price Performance

Shares of NASDAQ:ERNA opened at $2.15 on Tuesday. The company has a market cap of $11.63 million, a P/E ratio of -0.53 and a beta of 4.16. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 3.03. Eterna Therapeutics Inc. has a 52 week low of $0.84 and a 52 week high of $3.45. The business has a fifty day simple moving average of $2.00 and a 200-day simple moving average of $1.73.

Eterna Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($1.14) EPS for the quarter. The firm had revenue of $0.02 million during the quarter.

About Eterna Therapeutics

Eterna Therapeutics Inc operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.